Adenovirus 36 infection and obesity risk: current understanding and future therapeutic strategies. Issue 2 (4th March 2022)

• Record Type: Journal Article
• Authors: Cancelier, Ana Carolina Lobor; Schuelter-Trevisol, Fabiana; Trevisol, Daisson José; Atkinson, Richard L.
• Is Part Of: Expert review of endocrinology & metabolism. Volume 17:Issue 2(2022)
• Page Start: 143
• Page End: 152
• Publication Date: 2022-03-04
• Subjects: Adipocytes and tissue -- E4orf1 gene -- glucose metabolism -- vaccines; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1080/17446651.2022.2044303
• Languages: English
• ISSNs: 1744-6651

Abstract

ABSTRACT: Introduction: Obesity, a multifactorial disease caused by the interaction between genetic characteristics, metabolism, lifestyle, and environmental factors, is a major global health problem and is currently defined as a pandemic phenomenon. This disease is determined by an interaction of several factors, but the imbalance between energy consumption and expenditure seems to be the crucial point. In some cases, there is no linearity between exposure to those factors that cause the onset of obesity. A striking example of the occurrence of obesity despite no obvious risk factors is that of obesity induced by viral infections. The most important of such viruses appears to be human adenovirus 36 (Adv36). Areas covered: This review covers the relation between obesity and infection by Adv36 in humans. Also, discussed are the opportunities of prevention or treatment for the effects of Adv36 in human body. Expert opinion: The role of Ad36 in the development of obesity has already been established. Future research should focus on the development of vaccines against this agent, drug discovery for infected individuals, and effective therapeutic uses of E4orf1 gene protein for diabetes and other diseases in clinical practice.